Launch the DAYBUE STIX powder formulation
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Feb 2026
- Due
- 30 Jun 2026
- Delivered
- Q2 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to be ready for the planned broader launch in early second quarter 2026.”
What we found
Evidence strength A What the grades mean
The company confirmed that the broader launch of DAYBUE STIX occurred in early the second quarter of 2026, consistent with its stated commitment.
-
A Acadia Pharmaceuticals Inc. 8-K filed 2026-05-06
“Full launch of DAYBUE STIX (trofinetide) in the U.S. is underway” ✓ confirmed on the page
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2026-08-05
“DAYBUE STIX was available on a limited basis starting in the first quarter of 2026 followed by a broader launch early in the second quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved -1.7% against the S&P 500 over the three sessions around the disclosure (5 May 2026 to 8 May 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- DAYBUE STIX powder formulation
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-ACAD-002603 · Corrections policy